ImmuPharma plc (LON:IMM – Get Free Report) rose 191.7% on Thursday . The stock traded as high as GBX 3.80 ($0.05) and last traded at GBX 3.50 ($0.04). Approximately 104,299,430 shares were traded during trading, an increase of 470% from the average daily volume of 18,292,627 shares. The stock had previously closed at GBX 1.20 ($0.01).
ImmuPharma Stock Up 191.7 %
The stock’s 50-day simple moving average is GBX 1.40 and its 200 day simple moving average is GBX 1.65. The firm has a market cap of £14.58 million, a P/E ratio of -350.00 and a beta of 1.53.
ImmuPharma Company Profile
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease.
See Also
- Five stocks we like better than ImmuPharma
- The 3 Best Retail Stocks to Shop for in August
- MercadoLibre: Latin America’s Digital Titan Just Got Cheaper
- The Risks of Owning Bonds
- Breaking Down Pegasystems, A Wedbush Top AI Pick for 2025
- Buy P&G Now, Before It Sets A New All-Time High
- Shutterstock and Getty: A $3.7 Billion Visual Content Giant
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
